CD8A and hepatocellular carcinoma: Future studies should investigate whether HOXA-AS3/miR-455-5p alters the activity of CD8+ T cells via the PD-1/PD-L1 axis and whether targeting HOXA-AS3 can increase the effectiveness of HCC immunotherapies based on PD-1/PD-L1 blockade.